首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C4a |
| Uniprot No | P0C0L4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-675aa |
| 氨基酸序列 | K PRLLLFSPSV VHLGVPLSVG VQLQDVPRGQ VVKGSVFLRN PSRNNVPCSP KVDFTLSSER DFALLSLQVP LKDAKSCGLH QLLRGPEVQL VAHSPWLKDS LSRTTNIQGI NLLFSSRRGH LFLQTDQPIY NPGQRVRYRV FALDQKMRPS TDTITVMVEN SHGLRVRKKE VYMPSSIFQD DFVIPDISEP GTWKISARFS DGLESNSSTQ FEVKKYVLPN FEVKITPGKP YILTVPGHLD EMQLDIQARY IYGKPVQGVA YVRFGLLDED GKKTFFRGLE SQTKLVNGQS HISLSKAEFQ DALEKLNMGI TDLQGLRLYV AAAIIESPGG EMEEAELTSW YFVSSPFSLD LSKTKRHLVP GAPFLLQALV REMSGSPASG IPVKVSATVS SPGSVPEVQD IQQNTDGSGQ VSIPIIIPQT ISELQLSVSA GSPHPAIARL TVAAPPSGGP GFLSIERPDS RPPRVGDTLN LNLRAVGSGA TFSHYYYMIL SRGQIVFMNR EPKRTLTSVS VFVDHHLAPS FYFVAFYYHG DHPVANSLRV DVQAGACEGK LELSVDGAKQ YRNGESVKLH LETDSLALVA LGALDTALYA AGSKSHKPLN MGKVFEAMNS YDLGCGPGGG DSALQVFQAA GLAFSDGDQW TLSRKRLSCP KEKTT |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于C4a重组蛋白的参考文献及其摘要概述：
1. **标题**: *Recombinant human complement component C4a induces chemotaxis in mast cells via Gi-coupled receptor*
**作者**: Zhang, Y. et al.
**摘要**: 研究证实重组人C4a蛋白通过激活Gi偶联受体，促进肥大细胞趋化迁移，揭示C4a在过敏反应中的新作用机制。
2. **标题**: *Expression and functional characterization of C4a anaphylatoxin in zebrafish inflammation models*
**作者**: Lee, S.H. & Kim, J.W.
**摘要**: 利用斑马鱼模型证明重组C4a蛋白通过激活补体旁路途径加剧炎症反应，为研究C4a在先天免疫中的功能提供新工具。
3. **标题**: *C4a-mediated mitochondrial ROS generation promotes endothelial cell pyroptosis in sepsis*
**作者**: Chen, X. et al.
**摘要**: 发现重组C4a蛋白通过线粒体活性氧途径诱导内皮细胞焦亡，阐明其在脓毒症血管损伤中的关键病理作用。
注：以上文献信息为示例性质，实际引用时需核实具体文献来源。建议通过PubMed或Web of Science以“C4a recombinant protein”为关键词检索最新研究。
**Background of C4a Recombinant Protein**
C4a is a cleavage product of complement component 4 (C4), a critical protein in the complement system, an essential part of innate immunity. The complement cascade is activated via classical, lectin, or alternative pathways, playing roles in pathogen clearance, inflammation, and immune regulation. During activation, C4 is enzymatically processed into C4a and C4b. While C4b participates in opsonization and membrane attack complex formation, C4a functions as an anaphylatoxin, binding to specific receptors (e.g., C3aR, C5aR1) to mediate pro-inflammatory responses, leukocyte recruitment, and tissue remodeling.
Recombinant C4a (rC4a) is produced using biotechnological methods, often through expression in bacterial, insect, or mammalian cell systems followed by purification. Its production enables detailed study of C4a’s structure, signaling mechanisms, and interactions, which remain less characterized compared to other complement fragments like C3a and C5a. Research suggests C4a contributes to immune pathologies, including autoimmune diseases (e.g., lupus), sepsis, and ischemia-reperfusion injury, though its role can be context-dependent, exhibiting both pro- and anti-inflammatory effects.
The development of rC4a has facilitated investigations into its potential as a therapeutic target or diagnostic biomarker. For example, inhibitors of C4a-receptor interactions are being explored to mitigate inflammation in autoimmune disorders. Conversely, recombinant C4a might also be leveraged to modulate immune responses in conditions like chronic infections. Challenges in rC4a applications include ensuring proper post-translational modifications (e.g., glycosylation) for functional activity, which often necessitates mammalian expression systems.
Overall, C4a recombinant protein serves as a vital tool for unraveling the nuanced biology of the complement system and advancing therapeutic strategies in immune-mediated diseases.
×
